Device Comparison Glossary: Ulthera, Sofwave, Thermage, Shurink

I have a confession that I think most people who research these devices honestly share. After three trips into the Gangnam aesthetic-clinic circuit, I could comfortably define MFU, RF, SMAS, and neocollagenesis in isolation — but the moment a consultation moved into comparison mode, I lost the thread. Is Sofwave's SUPERB transducer really at the same depth as Ultherapy's 1.5mm? Is Thermage AccuREP doing the same thing as Ultherapy Prime's mapping? Is a Shurink line equivalent to an Ulthera line, energy-wise? Are head-to-head studies actually head-to-head, or are they against placebo? This glossary is the cleaned-up version of the comparison-mode notebook I started keeping after my fourth Gangnam trip. Fifty-five terms organized A to Z, all of them specifically about cross-device comparison vocabulary — mechanism differences, depth-of-effect differences, study-methodology caveats, real-world-versus-RCT framing. Plain English. Parenthetical Rachel-tone notes where they actually matter. None of it medical advice. It is the working vocabulary that lets you read a side-by-side device card without nodding along.

A — AccuREP, Against-placebo design, Applicator count

Section A covers three terms that show up early in any device-comparison conversation.

AccuREP (Thermage FLX comparison context)

Thermage FLX's automatic energy calibration feature — short for "accurate repair." In a comparison context, AccuREP is the Thermage equivalent to Ultherapy's imaging guidance, but the analogy is loose: AccuREP measures tissue impedance and adjusts RF energy zone-by-zone, while DeepSEE shows the practitioner the actual tissue layers visually. Both are real-time feedback systems; only one is visualization. (Tip: a clinic that markets "smart calibration" on Thermage and "imaging guidance" on Ultherapy as if they're the same feature is conflating two different categories of feedback.) See also: DeepSEE, imaging guidance, Thermage FLX.

Against-placebo study design

A clinical trial where the active device is compared against a sham treatment (no real energy, just contact). Most FDA clearance studies for energy-based devices are against-placebo or against-no-treatment, not head-to-head against another device. This matters when reading marketing claims — a device that "outperformed control" did not necessarily outperform a competitor. (Tip: ask whether the cited study is head-to-head or against-placebo. The honest answer is almost always against-placebo, which is fine for clearance but not for cross-device superiority claims.) See also: head-to-head trial, blinded trial, sponsor disclosure.

Applicator count (per session)

The number of distinct applicators or transducers used during a single session. Ultherapy Prime typically uses three transducers (1.5mm, 3mm, 4.5mm); Sofwave uses one SUPERB transducer; Thermage FLX uses one Total Tip 4.0 (or area-specific tip); Shurink uses two to three transducers; Doublo uses two to three. The count alone does not determine quality, but it does correlate with depth coverage. (Tip: a one-applicator session is not automatically inferior — Sofwave's parallel-beam geometry covers more area per shot than a focal-point applicator.) See also: transducer, SUPERB transducer, line count.

B — Blinded trial, Broad indication overlap

Section B covers two terms anchored in study methodology and FDA-clearance language.

Blinded vs open-label

In a blinded trial, the patient (single-blind) or both patient and assessor (double-blind) do not know which treatment was delivered. In an open-label trial, everyone knows. Most aesthetic device studies are open-label or single-blind on the assessor side, since fully blinding a patient to a treatment they can feel is hard. (Tip: blinded photography assessment by an independent reviewer is the gold standard claim — when you see "blinded photographic evaluation" in a study summary, it is more credible than self-reported satisfaction scores.) See also: against-placebo design, real-world satisfaction, sponsor disclosure.

Broad indication overlap

When two devices share FDA clearance for the same anatomical indication — for example, both Ultherapy and Sofwave are FDA-cleared for brow lift, neck lift, and submental lift, but the mechanism reaching that result is different. Indication overlap does not mean the devices produce identical results or are interchangeable in protocol. (Tip: indication overlap is the marketing department's friend — it lets a clinic legally describe Sofwave as "FDA-cleared for the same areas as Ultherapy" while leaving the depth and mechanism conversation for later.) See also: FDA clearance, on-label vs off-label, primary endpoint.

C — Cost tier, Combination protocol, Comparative methodology, Contact pressure feedback

Section C covers four cross-device terms that consistently come up in package conversations.

Cost tier (cross-device)

The relative pricing band of a treatment, usually expressed as $ / $$ / $$$ in editorial copy. In Korean clinic markets the rough order is Doublo and Shurink at the budget tier, Sofwave at the mid tier, and Ultherapy Prime and Thermage FLX at the premium tier. The same patient may receive any of these for the same indication. (Tip: cost tier correlates more with consumables and licensing than with actual energy delivered — a budget HIFU at full line count can deliver more total joules than a premium MFU at "light" packaging.) See also: line count, device generation, real-world satisfaction.

Combination protocol

A treatment plan that uses two or more energy modalities in a single session or sequenced over several weeks — for example, MFU at the SMAS plus monopolar RF at the volumetric dermis, or Sofwave at the mid-dermis plus Thermage FLX at the deeper RF column. The categorical reasoning is that the modalities are complementary rather than competitive. (Tip: most experienced Gangnam practitioners run combination protocols rather than single-device protocols — when a clinic offers only one device, ask why.) See also: device sequencing, complementary not competitive.

Comparative study methodology

The set of design choices that makes a head-to-head device comparison valid: matched patient cohorts, identical assessment timepoints, blinded photographic review, and pre-registered primary endpoints. Most published comparisons fall short on at least one of these dimensions. (Tip: when a marketing claim cites "a study showed Device A outperformed Device B," check the methodology — small open-label studies with sponsor funding are common, and they are not the same as a properly designed head-to-head RCT.) See also: head-to-head trial, primary endpoint, sponsor disclosure.

Contact pressure feedback

A real-time sensor on a device handpiece that signals whether the operator is pressing with the correct force on the skin. Sofwave incorporates contact-pressure verification on the SUPERB transducer; Thermage FLX uses tissue impedance feedback (AccuREP) which serves a related purpose; Ultherapy and Shurink rely more on visual coupling-gel confirmation. (Tip: contact-pressure feedback is one of the underrated quality differentiators between device generations — better feedback usually means more uniform energy delivery across the treatment.) See also: AccuREP, sensors and verification, transducer.

D — Depth-of-effect, Doublo Gold, Downtime category, Duration of results

Section D covers four terms central to cross-device comparison.

Depth-of-effect (cross-device)

The skin-layer target a device is designed to reach. Ultherapy treats 1.5mm, 3mm, and 4.5mm — the third depth is the SMAS. Sofwave treats one depth, approximately 1.5mm in the mid-dermis, with no SMAS targeting. Thermage FLX delivers volumetric heating across 2-4mm via monopolar RF — not a single "depth" but a heating column. Shurink and Doublo target three depths similar to Ultherapy but without imaging guidance. (Tip: "depth" is not interchangeable across categories — RF volumetric depth and MFU focal depth describe different physics.) See also: focal point, SMAS, volumetric heating.

Doublo Gold

An updated generation of the Korean-manufactured Doublo HIFU platform, marketed with refined transducer ergonomics and updated console software. Doublo Gold is to original Doublo what Ultherapy Prime is to original Ultherapy — a hardware refresh, not a different category. The underlying HIFU mechanism and three-depth architecture are unchanged. (Tip: "Doublo Gold" in marketing copy is genuine generation language; "Doublo Premium" is sometimes a clinic-side relabel — ask which generation the device console reads.) See also: Doublo, HIFU, device generation.

Downtime category (cross-device)

The recovery profile a treatment produces. Most MFU, HIFU, and Sofwave sessions fall into the "none to mild" category — transient redness or swelling for a few hours. Thermage FLX similarly has minimal visible downtime. Microneedling RF and ablative laser sit in a categorically different downtime bracket of three to seven days. The five comparison devices in this glossary all share the "most none" downtime category. (Tip: "no downtime" is roughly true for Ulthera, Sofwave, Thermage, Shurink, Doublo — the more honest framing is "no social downtime," since some patients experience hours of redness.) See also: real-world satisfaction, results onset timing.

Duration of results (months)

The window over which a treatment's neocollagenesis-driven lift is visible before maintenance is recommended. Patients report Ultherapy results lasting 12-18 months, Sofwave 9-12 months, Thermage FLX 12-24 months, Shurink 6-12 months, Doublo 6-12 months. These ranges overlap heavily and depend more on individual collagen response than on device choice. (Tip: "lasts two years" in marketing usually refers to the longest end of the cohort range, not the median — ask for the median duration if the clinic has internal data.) See also: maintenance interval, neocollagenesis, real-world satisfaction.

E — Energy range (J/cm²), Endpoints (primary)

Section E covers two terms central to numerical comparison and study reading.

Energy range comparison (J/cm² cross-device)

The joules-per-square-centimeter delivered by each platform across a typical session. Ultherapy lines deliver about 0.18 to 1.2 J per pulse, totaling several thousand joules across a full-face protocol. Sofwave SUPERB delivers similar per-shot energy but covers more area per shot due to the parallel-beam geometry. Thermage FLX bulk-heating energy is hard to compare directly — it is a column, not a focal point. Shurink and Doublo land in the same per-shot range as Ultherapy but with broader focal spots. (Tip: total session energy is more meaningful than per-shot energy when comparing — ask for the total joules figure.) See also: line count, fluence, J/cm².

Primary endpoint differences

The pre-registered measurement a study uses to judge success. Ultherapy clearance studies used blinded photographic improvement at 90 days as primary endpoint. Sofwave clearance used blinded photographic improvement at 12 weeks. Thermage clearance studies have used both photographic and patient-reported outcomes. Different primary endpoints make cross-study comparison hazardous. (Tip: when a marketing claim cites "X% improvement," the meaningful question is what improvement on what scale at what timepoint — different studies use different scales.) See also: blinded vs open-label, comparative methodology, FDA clearance.

F — FDA clearance, Focal vs surface heating, Frequency (transducer)

Section F covers three terms that consistently come up in regulatory and physics conversations.

FDA clearance (cross-device status)

The U.S. regulatory status of a device for a specific indication. Ultherapy was FDA-cleared in 2009 for non-surgical brow lift, expanded to neck and submental over time. Sofwave received clearance in 2019 for similar indications. Thermage FLX is the current FLX-generation iteration of long-cleared monopolar RF. Shurink and Doublo are KFDA-cleared (Korean Ministry of Food and Drug Safety) but not FDA-cleared in the U.S. (Tip: FDA clearance and KFDA clearance are not the same thing — both are real, but they reference different regulatory bodies and different review depths.) See also: KFDA Class II vs III, on-label vs off-label.

Focal vs surface heating

The categorical mechanism distinction between focused-ultrasound devices and bulk-heating RF devices. MFU and HIFU produce thermal effect at small focal points at known depths, leaving surrounding tissue largely unaffected. Monopolar RF heats a column of tissue volumetrically. Sofwave occupies a hybrid space — parallel-beam focal heating at one depth across a wider line than single-point focal. (Tip: focal heating preserves more surrounding tissue but addresses a smaller volume; surface or bulk heating addresses more volume but is less precise about layer.) See also: bulk heating, micro-coagulation, SUPERB transducer.

Frequency (transducer cross-device)

The MHz rating of an ultrasound transducer, which determines focal depth — higher frequency means shallower focal point, lower frequency means deeper. Ultherapy uses 7 MHz at 4.5mm, 7 MHz at 3mm, and 10 MHz at 1.5mm. Sofwave SUPERB operates around 2 MHz. Shurink and Doublo use comparable frequency-depth pairs to Ultherapy. (Tip: the frequency-depth physics is identical across MFU and HIFU — the differentiator is focal-spot precision, imaging guidance, and beam geometry, not the underlying frequency math.) See also: MFU, HIFU, focal point.

H — Head-to-head trial

Section H covers the single most important term in study-methodology comparison.

Head-to-head trial

A clinical trial directly comparing two or more active devices on matched patient cohorts at identical timepoints. Genuine head-to-head trials between Ultherapy and Sofwave, or Thermage and Ultherapy, exist but are rare and almost always sponsor-funded by one of the comparators. Most published comparisons are split-face designs (one device per side of the same patient) rather than separate cohorts. (Tip: split-face is the most rigorous head-to-head design for aesthetic devices — both treatments hit the same patient, controlling for individual response variation. Ask whether a cited study was split-face or parallel-cohort.) See also: against-placebo design, comparative methodology, sponsor disclosure.

I — Indication overlap, Imaging vs impedance feedback

Section I covers two terms that show up in clearance and feedback-system comparisons.

Indication overlap (between devices)

The set of FDA or KFDA clearances shared between two devices. Ultherapy and Sofwave overlap on brow, neck, and submental lift; Ultherapy and Thermage overlap on neck and decolletage in some clearance scopes; Shurink and Doublo overlap on facial lifting under KFDA clearance. Indication overlap is what allows a clinic to legally describe a budget device as "used for the same areas as Ultherapy." (Tip: the overlap claim is technically true but does not mean equivalent results — the mechanism-and-depth conversation is the more honest one.) See also: broad indication overlap, FDA clearance, KFDA Class II vs III.

Imaging vs impedance feedback

The two categorical feedback systems on premium energy devices. Ultherapy uses imaging feedback (DeepSEE shows actual tissue layers in real time on the device screen); Thermage FLX uses impedance feedback (AccuREP measures electrical resistance and adjusts RF energy zone-by-zone). Sofwave uses contact-pressure feedback. Shurink and Doublo generally rely on coupling-gel and skin-marking feedback rather than electronic verification. (Tip: visualization is the single most valuable feedback type because it confirms anatomical landing — impedance and pressure confirm mechanical conditions, not anatomy.) See also: AccuREP, DeepSEE, contact pressure feedback.

K — KFDA Class II vs III

Section K covers the Korean regulatory classification that determines which clinics can legally operate a device.

KFDA Class II vs III

Korea's medical device classification system, where Class II is moderate-risk and Class III is higher-risk. Most aesthetic energy devices used in face protocols are KFDA Class II or Class III depending on energy output and indication. Ultherapy, Sofwave, Thermage FLX, Shurink, and Doublo are all KFDA-registered for facial lifting indications, with classification varying by exact device generation. (Tip: KFDA classification is not a quality ranking — it is a risk-and-supervision tier. A Class III device requires more clinical oversight, but "Class III" in marketing copy does not automatically mean better results.) See also: FDA clearance, on-label vs off-label.

L — LDM-MED, Line count, Line packaging

Section L covers three terms that come up in package and protocol comparisons.

LDM-MED

A German-manufactured ultrasound technology — Local Dynamic Micro-massage — using rapidly switching frequencies to produce mechanical micro-vibration at multiple depths simultaneously. LDM-MED is categorically different from MFU, HIFU, and Sofwave's SUPERB technology — it is shallower, gentler, and the categorical claim is anti-inflammatory and barrier-supportive rather than primarily lifting. Less common in Korean clinics, more popular in European medical-spa contexts. (Tip: LDM-MED is sometimes offered alongside MFU as a recovery or maintenance modality, not as a substitute.) See also: ultrasound, MFU, combination protocol.

Line count (cross-device)

The number of treatment lines delivered during an MFU or HIFU session. A standard full-face Ultherapy protocol is 800-1,000 lines across the three depths; Shurink full-face protocols range from 600 to 1,200 lines depending on packaging; Doublo similar. Sofwave does not use "lines" but "placements" of the SUPERB transducer; Thermage does not use lines at all and counts in pulses. (Tip: line count is not directly comparable between Ultherapy and Shurink — same number, different focal-spot precision.) See also: line packaging, transducer, pulse count.

Line-count packaging vs hourly

The two main pricing structures for energy-based treatments in Korean clinics. Line-count packaging quotes by lines delivered (e.g., "600 lines for X price"); hourly packaging quotes by minutes of practitioner time. Line-count is more transparent for MFU and HIFU; hourly is more common for combination protocols. (Tip: if a clinic quotes you a price without specifying line count or session length, ask for the breakdown — "a Shurink package" can mean 300 lines or 1,000 lines, and the energy gap is enormous.) See also: line count, cost tier, treatment time per zone.

M — Mechanism comparison, Multi-device combination, Multi-pass vs single-pass

Section M covers three terms that anchor the mechanism-side comparison conversation.

Mechanism comparison (MFU vs RF vs SUPERB)

The three categorical mechanisms across the comparison-device set. MFU (Ultherapy, Shurink, Doublo) produces focal-point thermal coagulation at known depths via focused ultrasound. RF (Thermage FLX) produces volumetric bulk heating via radiofrequency current through tissue. SUPERB (Sofwave) produces parallel-beam thermal effect at the mid-dermis via Synchronous Ultrasound Parallel Beam — a hybrid between focal MFU and broader heating. (Tip: when comparing devices, mechanism-first is more useful than depth-first or brand-first — the mechanism predicts which other modalities pair well.) See also: MFU, monopolar RF, SUPERB transducer.

Multi-device combination protocol

A treatment plan combining two or more devices across a course of sessions — for example, Ultherapy at the SMAS depth plus Thermage FLX for volumetric tightening, sequenced four to six weeks apart. Most premium Gangnam protocols are multi-device rather than single-device. The reasoning is that MFU addresses structural-layer lift while RF addresses dermal-layer tightening, and the modalities are complementary rather than competitive. (Tip: the question "which one device should I pick?" is sometimes the wrong question — "which two devices and in what sequence?" is often the better one.) See also: combination protocol, device sequencing, complementary not competitive.

Single-pass vs multi-pass

The number of times the practitioner passes the handpiece over each treatment zone. Ultherapy is typically single-pass per depth at standard protocols; Sofwave is single-pass per placement. Thermage FLX is often delivered as multi-pass at varying energies (the MMRF approach). Shurink and Doublo can be either. (Tip: multi-pass is not automatically better — for MFU, a second pass at the same depth can produce diminishing returns and risk; for RF, multi-pass at varying energies is often the safer protocol than a single high-energy pass.) See also: MMRF, energy range, transducer.

O — On-label vs off-label, Onset of results

Section O covers two terms tied to clearance and timing.

On-label vs off-label

On-label use means the device is being used for an FDA- or KFDA-cleared indication; off-label means use outside cleared indications. Most aesthetic devices have a few cleared indications and many additional uses that physicians legally apply at their discretion. Ultherapy is on-label for brow, submental, neck; off-label for cheek, decolletage in some jurisdictions. Sofwave similar. Thermage FLX has broader on-label scope. (Tip: off-label use is not unethical — it is how aesthetic medicine evolves — but it is worth knowing whether your specific indication is on-label or off-label for the device.) See also: FDA clearance, KFDA Class II vs III, indication overlap.

Onset of results timing

The window between treatment and visible improvement. Ultherapy patients typically see partial onset at 4-8 weeks and full effect at 12-24 weeks. Sofwave is similar — gradual onset over 12 weeks. Thermage FLX shows initial tightening at the session and continued improvement over 3-6 months as collagen remodels. Shurink and Doublo show similar curves to Ultherapy but with more variability. (Tip: "immediate lift" claims for any of these devices are usually a transient inflammation effect, not the real result — the real result is the 90-day-plus collagen response.) See also: neocollagenesis, duration of results.

P — Pain category, Parallel beam vs focal point

Section P covers two terms central to patient-experience comparison.

Pain category (cross-device)

The patient-experience comparison that matters most in real-world satisfaction. Ultherapy is generally rated as moderate pain — the focal coagulation at SMAS depth produces a sharp "zing" sensation per line. Sofwave is reported as milder, since the parallel-beam delivery distributes energy more broadly. Thermage FLX is described as tolerable with the integrated cooling — short bursts of heat-then-cold. Shurink is moderate, similar to Ultherapy but with more variation by clinic. Doublo is moderate to sharp at higher settings. (Tip: pain tolerance is highly individual — the cross-device ranking holds on average but flips for some patients.) See also: real-world satisfaction, contact pressure feedback.

Parallel beam vs focal point

The categorical geometry distinction between Sofwave SUPERB (seven parallel beams firing simultaneously across a 16mm line) and conventional focal-point MFU/HIFU (a single focal spot per shot). Parallel-beam covers more surface area per shot but at a fixed depth (~1.5mm); focal-point covers less area per shot but lets the operator choose depth (1.5/3/4.5mm). (Tip: parallel-beam is faster per zone but cannot reach SMAS; focal-point reaches SMAS but takes more time to cover an equivalent area. Different tools, different jobs.) See also: SUPERB transducer, focal point, treatment time per zone.

R — Real-world satisfaction, RCT vs real-world

Section R covers two terms tied to outcome interpretation.

Real-world satisfaction (vs clinical trial outcome)

Patient-reported outcomes outside the controlled clinical-trial environment. Real-world satisfaction is generally lower than RCT-reported satisfaction across all five comparison devices, because RCT patients are pre-screened for ideal candidacy, treated by experienced injectors at higher energy levels, and followed up rigorously. (Tip: real-world satisfaction at 60-75% is the honest range for most premium energy devices when applied across mixed candidacy and protocol quality. Marketing materials cite the higher RCT numbers.) See also: comparative methodology, primary endpoint, sponsor disclosure.

RCT vs real-world

Randomized controlled trial outcomes versus everyday clinic outcomes. RCT settings have selection bias (best candidates), protocol fidelity (full energy, full line count), and assessment rigor (blinded photographic review). Real-world settings have mixed candidacy, varying protocols, and self-reported outcomes. The gap between RCT and real-world is real and consistent — usually 15-25 percentage points. (Tip: when reading a comparison study, ask whether the result generalizes to a clinic that does "light" packaging and abbreviated protocols — usually it does not.) See also: real-world satisfaction, line count, comparative methodology.

S — Sensors and verification, Sponsor disclosure, Summary chart features

Section S is dense — three terms anchoring the methodology-and-disclosure conversation.

Sensors and verification (cross-device)

The set of in-device sensors that verify treatment quality in real time. Ultherapy uses ultrasound imaging plus coupling-gel detection; Sofwave uses contact-pressure sensors plus parallel-beam alignment verification; Thermage FLX uses tissue-impedance feedback; Shurink and Doublo rely more on visual practitioner verification than electronic. (Tip: more sensors generally mean more uniform delivery across the same protocol — but a great practitioner with fewer sensors can outperform a mediocre practitioner with more. Sensors raise the floor, not the ceiling.) See also: imaging vs impedance feedback, contact pressure feedback.

Sponsor disclosure

The conflict-of-interest statement at the end of a clinical study disclosing who funded it. Most aesthetic device comparison studies are sponsored by one of the comparator manufacturers, which is not automatically disqualifying but is essential context. Merz Aesthetics sponsors Ultherapy studies; Sofwave Medical sponsors Sofwave studies; Solta sponsors Thermage studies. (Tip: when a study favors the sponsor's device, the magnitude of the effect deserves more skepticism than the direction. Independent studies are rare and worth seeking out.) See also: comparative methodology, head-to-head trial, blinded vs open-label.

Summary chart features

The standard feature columns most editorial device-comparison charts use — name, mechanism, depth, energy unit, session time, downtime, FDA clearance, cost tier, results onset, results duration. A good summary chart shows the categorical positioning rather than ranking. (Tip: a summary chart that ranks devices #1 / #2 / #3 is making editorial claims the underlying physics does not support — the honest chart shows trade-offs, not winners.) See also: comparative methodology, cost tier, indication overlap.

T — Treatment time per zone, Transducer count

Section T covers two terms that show up in workflow and per-applicator comparisons.

Treatment time per zone

The minutes required to treat a defined facial zone with a given device. Ultherapy Prime is roughly 30-50% faster per zone than original Ultherapy due to the upgraded mapping and transducer ergonomics. Sofwave is faster per zone than focal-point MFU due to the parallel-beam geometry. Thermage FLX is faster per zone than original Thermage due to the larger Total Tip 4.0. (Tip: faster per zone is not automatically a quality metric — it can mean better ergonomics or it can mean fewer lines per area. Ask whether the speed comes from coverage geometry or reduced line count.) See also: line count, applicator count, parallel beam vs focal point.

Transducer count (cross-device)

The number of distinct transducer types a device platform uses. Ultherapy Prime uses three transducers (1.5mm, 3mm, 4.5mm); Shurink uses three to four; Doublo uses two to three; Sofwave uses one SUPERB transducer; Thermage FLX uses tips rather than transducers (Total Tip, Eye Tip, Body Tip). The transducer count correlates with depth versatility but not with quality at any single depth. (Tip: a one-transducer Sofwave is not categorically inferior to a three-transducer Ultherapy — they are addressing different layers with different geometries.) See also: applicator count, transducer, depth-of-effect.

U — Ultherapy SPT, Ultherapy Prime

Section U covers two Ulthera-specific generations that consistently confuse comparison shoppers.

Ultherapy SPT (See, Plan, Treat)

The branded protocol framework Merz Aesthetics uses to describe the Ultherapy workflow — the practitioner first "sees" tissue layers via DeepSEE imaging, "plans" the line distribution per depth, then "treats" with focal-point pulses. SPT is not a separate device generation, it is the name for the visualization-driven workflow that distinguishes MFU from HIFU. (Tip: "Ultherapy SPT" in marketing copy means the imaging-guided protocol, not a hardware feature — every Ultherapy and Ultherapy Prime device runs SPT by default.) See also: Ultherapy Prime, DeepSEE, imaging guidance.

Ultherapy Prime

The current-generation Ulthera device, released as an upgrade to the original Ultherapy platform. Prime features improved transducer ergonomics, faster per-zone mapping (roughly 30-50% faster), updated imaging clarity, and patient-comfort refinements like a redesigned coupling pad. The underlying frequency-depth architecture (1.5mm, 3mm, 4.5mm) is unchanged. (Tip: Prime versus original is a hardware-and-software refresh, not a different category — the depth and protocol logic are identical.) See also: Ulthera, device generation, treatment time per zone.

V — V Max, Volumetric heating

Section V covers two terms that show up at the budget and physics ends of the comparison.

V Max

A Korean-manufactured HIFU device occasionally encountered in budget-tier Korean clinics, marketed as a multi-depth focused-ultrasound platform similar to Shurink and Doublo. V Max sits in the same HIFU category as Shurink and Doublo — focal-point ultrasound at multiple depths, no real-time imaging guidance. Less commonly listed in editorial comparison charts because the device generation and clinical evidence base are thinner than Shurink or Doublo. (Tip: V Max is functionally adjacent to Shurink and Doublo — if a clinic offers V Max as a primary recommendation, ask whether they also operate Shurink or Ultherapy for context.) See also: HIFU, Shurink, Doublo.

Volumetric heating

Heating a three-dimensional volume of tissue rather than depositing energy at discrete focal points. Monopolar RF (Thermage FLX) is the canonical volumetric modality — the goal is to bring a column of dermis-to-subcutaneous tissue to roughly 40-45°C. Volumetric heating is the categorical opposite of MFU's focal-point approach and is one of the reasons MFU and RF combine well in protocol design. (Tip: when a clinic talks about "global tightening" or "volumetric lift," they almost always mean RF volumetric heating, not MFU focal points.) See also: bulk heating, monopolar RF, mechanism comparison.

K — Korean clinic preference patterns

Section K (continued) covers one final pattern term that captures real-world device-mix observations.

Korean clinic preference patterns

The observed device-mix distribution across Korean aesthetic clinics. Premium clinics in Gangnam typically operate Ultherapy Prime plus Thermage FLX plus Sofwave as the core MFU+RF+SUPERB combination, with optional Shurink or Doublo at lower price tiers. Mid-tier clinics commonly operate Shurink plus Thermage. Budget clinics often operate Doublo or V Max plus a generic RF. (Tip: the device mix at a clinic is a more honest signal than the marketing copy — a clinic that operates four or five different categories of energy device is investing in protocol versatility, not just one platform.) See also: cost tier, multi-device combination protocol, device generation.

Complementary not competitive (editorial framing)

The editorial framing premium clinics use to describe combination protocols — that MFU and RF are not rivals but partners addressing different layers, with the SMAS-targeting work belonging to MFU and the volumetric dermal work belonging to RF. The framing has a real physics basis: focal-point and bulk-heating mechanisms produce categorically different result profiles. (Tip: when a clinic frames Ultherapy and Thermage as complementary rather than competitive, that usually signals a more sophisticated protocol approach than a clinic that pushes one device as superior.) See also: combination protocol, mechanism comparison, multi-device combination protocol.

Device sequencing

The order in which devices are delivered within a multi-device protocol. The standard premium-Gangnam sequence is MFU first (Ultherapy at SMAS for structural lift), followed by RF four to six weeks later (Thermage FLX for volumetric dermal tightening), with Sofwave occasionally inserted as a mid-dermis bridge. The sequencing reasoning is that the structural layer responds more slowly than the dermal layer, so giving MFU a head start on neocollagenesis lets the dermal tightening land into a structurally tightened scaffold. (Tip: "same day, two devices" sessions are real but not the standard premium sequence — separate sessions usually produce cleaner outcomes.) See also: combination protocol, complementary not competitive, neocollagenesis.

Maintenance interval

The recommended re-treatment cadence after the initial protocol. Ultherapy maintenance is typically 12-18 months; Sofwave 9-12 months; Thermage FLX 12-24 months; Shurink and Doublo 6-12 months. The maintenance window is shorter than the duration-of-results window because clinics generally recommend re-treatment before the result fully fades. (Tip: "do I need to re-treat in a year" is a different question than "will the result still be visible in a year" — the maintenance interval is conservative on purpose.) See also: duration of results, neocollagenesis, real-world satisfaction.

Candidacy overlap

The patient-profile range across which multiple comparison devices are reasonable choices. Most non-surgical lift candidates — patients with mild to moderate laxity, intact skin quality, and no active treatment contraindications — qualify for Ultherapy, Sofwave, Thermage, Shurink, and Doublo all at once. The choice between them then becomes a matter of mechanism preference, depth target, cost tier, and pain tolerance. (Tip: "which device am I a candidate for" is rarely the right question — the better question is "given that I am a candidate for several, what mechanism and depth makes sense for my specific concern.") See also: cost tier, depth-of-effect, real-world satisfaction.

Frequently asked questions

If I only have time to learn ten of these terms before my Gangnam consultation, which ten?

Mechanism comparison (MFU vs RF vs SUPERB), depth-of-effect, focal vs surface heating, FDA clearance versus KFDA classification, head-to-head trial versus against-placebo, sponsor disclosure, real-world satisfaction versus RCT, line count, cost tier, and combination protocol. Those ten cover the categorical, regulatory, and study-methodology vocabulary of every cross-device conversation. Patients report the consultation reads completely differently once these ten anchor concepts are in place.

Is Sofwave really comparable to Ultherapy, or is the comparison marketing-driven?

Both. Sofwave and Ultherapy share FDA-cleared indications for brow, neck, and submental lift, which makes them legitimately comparable at the indication level. They are not comparable at the depth or mechanism level — Sofwave reaches mid-dermis only, Ultherapy reaches SMAS at 4.5mm. Patients report Sofwave as a milder treatment with a different result profile, not an Ultherapy substitute. The categorical claim differs even when the FDA-cleared indication overlaps.

Are Shurink and Doublo just budget Ultherapy, or genuinely different?

They are HIFU, not MFU. Both share the focused-ultrasound mechanism and three-depth architecture but lack imaging guidance — the practitioner cannot see the tissue layers in real time. Patients report Shurink and Doublo deliver decent results at experienced clinics with strong protocol fidelity, but the result variability is higher than Ultherapy because the focal-point landing is less precisely confirmed. Cost tier reflects that visualization-and-precision gap, not just brand premium.

How do I read a head-to-head device comparison study honestly?

Start at the methodology section, not the conclusion. Check whether the trial was head-to-head or against-placebo, whether assessment was blinded, what the primary endpoint was and at what timepoint, who sponsored the study, and whether the design was split-face or parallel-cohort. Patients report most published comparisons fall short on at least one of these dimensions — which does not invalidate them but does mean the conclusion needs context-aware reading.

Should I expect the same result from a single device versus a combination protocol?

No, and this is one of the most underappreciated parts of cross-device comparison. Single-device protocols address one mechanism and one depth class; combination protocols (MFU + RF, or MFU + SUPERB) address different layers with complementary mechanisms. Patients report combination protocols generally produce additive results at the cost of higher session price and longer total protocol time. Most premium Gangnam clinics default to combination, not single-device.

What is the most overhyped term in cross-device marketing copy?

"Equivalent to Ultherapy" or "as effective as Thermage," usually applied to budget HIFU or generic RF platforms. The equivalence claim almost always rests on indication overlap rather than mechanism, depth, or sensor parity. Patients report the more honest framing is "addresses similar concerns at a different price tier with different precision." Categorical equivalence is rarely supported by head-to-head evidence; pricing-tier positioning is.

Why do downtime and pain category seem so similar across these five devices?

Because all five are non-ablative, non-needle-penetrating, surface-sparing modalities. They all heat below the skin without breaking it, which puts them in the same broad downtime category — none-to-mild, with hours of redness or swelling at most. The pain comparison varies more — Sofwave milder, Ultherapy and Shurink moderate, Thermage tolerable with cooling — but the downtime convergence is real and is one of the main reasons this comparison set is grouped editorially.